This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human Carbonic Anhydrase IX / CA9 (38-414) Protein, His Tag (active enzyme)
catalog :
CA9-H5226
quantity :
50 ug, 1 mg
price :
350 USD, 2200 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
CA9-H5226
product name :
Human Carbonic Anhydrase IX / CA9 (38-414) Protein, His Tag (active enzyme)
quantity :
50 ug, 1 mg
price :
350 USD, 2200 USD
quantity & price :
$350/50ug,$2200/1mg (200ug × 5)
target :
Carbonic Anhydrase IX
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human Carbonic Anhydrase IX (38-414), His Tag (CA9-H5226) is expressed from human 293 cells (HEK293). It contains AA Gln 38 - Asp 414 (Accession # Q16790-1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>90% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human Carbonic Anhydrase IX (38-414), His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Formulation :
Lyophilized from 0.22 μm filtered solution in 20 mM MES, 100 mM NaCl, pH6.5. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Carbonic anhydrases (CAs) are a large family of zinc metalloenzymes. CAs form a family of enzymes that catalyze the rapid interconversion of carbon dioxide and water to bicarbonate and protons (or vice versa), a reversible reaction that occurs rather slowly in the absence of a catalyst. One of the functions of the enzyme in animals is to interconvert carbon dioxide and bicarbonate to maintain acid-base balance in blood and other tissues, and to help transport carbon dioxide out of tissues. The active site of most carbonic anhydrases contains a zinc ion. There are at least five distinct CA families (α, β, γ, δ and ε).
Carbonic anhydrase 9 (CA9 / CAIX) is also known as Membrane antigen MN (MN), Renal cell carcinoma-associated antigen G250, which belongs to the alpha-carbonic anhydrase family. CA9 / CAIX with an optimal activity at pH 6.49. Reversible hydration of carbon dioxide. CA IX participates in pH regulation. CA9 may be involved in the control of cell proliferation and transformation. CA-IX appears to be a novel specific biomarker for a cervical neoplasia.
References :
(1) Badger MR, Price GD, 1994, Annu. Rev. Plant Physiol. Plant Mol. Bio. 45: 369–392.
(2) Temperini C., et al., 2007, Bioorg. Med. Chem. Lett. 17:2210-2215.
(3) Hilvo M., et al., 2008, J. Biol. Chem. 283:27799-27809.
(4) Alterio V., et al., 2009, Proc. Natl. Acad. Sci. U.S.A. 106:16233-16238.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments